Comparing Bionomics (NASDAQ:BNOX) and Telomir Pharmaceuticals (NASDAQ:TELO)

Bionomics (NASDAQ:BNOX) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Insider and Institutional Ownership

15.9% of Bionomics shares are owned by institutional investors. 1.5% of Bionomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Bionomics and Telomir Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionomics	0	0	2	0	3.00
Telomir Pharmaceuticals	0	0	0	0	0.00

Bionomics presently has a consensus price target of $8.00, indicating a potential upside of 2,648.20%. Given Bionomics’ stronger consensus rating and higher probable upside, research analysts clearly believe Bionomics is more favorable than Telomir Pharmaceuticals.

Profitability

This table compares Bionomics and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bionomics	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-1,087.92%	-806.34%

Valuation and Earnings

This table compares Bionomics and Telomir Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionomics	$10,000.00	504.19	-$15.49 million	N/A	N/A
Telomir Pharmaceuticals	N/A	N/A	-$13.07 million	N/A	N/A

Telomir Pharmaceuticals has lower revenue, but higher earnings than Bionomics.

Summary

Bionomics beats Telomir Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.